Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Concert licenses deuterated version of dextromethorphan to Avanir

Executive Summary

Drug discovery company Concert Pharmaceuticals Inc. has licensed Avanir Pharmaceuticals Inc. (CNS and viral diseases) exclusive worldwide rights to multiple versions of dextromethorphan analogs that incorporate deuterium (d-DM). The agreement includes Concert’s CTP786 (formerly C10003), in preclinical studies for pain and pseudobulbar affect (PBA; sudden outbursts of uncontrollable emotional displays).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies